Market revenue in 2023 | USD 66.8 million |
Market revenue in 2030 | USD 180.8 million |
Growth rate | 15.3% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.29% in 2023. Horizon Databook has segmented the Middle East & Africa crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
This region was observed to have the lowest market penetration in 2019. However, in the coming years, the MEA market is expected to witness considerable growth, owing to the growing importance of CRISPR technologies in human disease treatment.
Moreover, clinical studies conducted on the use of gene-editing in agriculture is expected to impact the growth of MEA’s GM crop industry. Researchers are continuously employing this technology for the development of novel therapies.
In May 2018, researchers from the United Arab Emirates University successfully used CRISPRCas9 technology to gain insights on disease mechanisms, finally helping them design novel therapies. The UAE ranks sixth in the globe in terms of prevalence of birth defects, which is expected to propel the demand for novel therapies.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa crispr and cas genes market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account